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Abstract
Current inhibitors of angiogenesis comprise either therapeutic antibodies (e.g. bevacicumab binding to VEGF-A) or small
molecular inhibitors of receptor tyrosin kinases like e.g. sunitinib, which inhibits PDGFR and VEGFR. We have recently
identified cyclin-dependent kinase 5 (Cdk5) as novel alternative and pharmacologically accessible target in the context of
angiogenesis. In the present work we demonstrate that trisubstituted pyrazolo[4,3-d]pyrimidines constitute a novel class of
compounds which potently inhibit angiogenesis. All seven tested compounds inhibited endothelial cell proliferation with
IC50 values between 1 and 18 mM. Interestingly, this seems not to be due to cytotoxicity, since none of them showed acute
cytotoxic effects on endothelial cells at a concentration of 10 mM,. The three most potent compounds (LGR1404, LGR1406
and LGR1407) also inhibited cell migration (by 27, 51 and 31%, resp.), chemotaxis (by 50, 70 and 60% in accumulative
distance, resp.), and tube formation (by 25, 60 and 30% of total tube length, resp.) at the non-toxic concentration of 10 mM.
Furthermore, angiogenesis was reduced in vivo in the CAM assay by these three compounds. A kinase selectivity profiling
revealed that the compounds prevalently inhibit Cdk2, Cdk5 and Cdk9. The phenotype of the migrating cells (reduced
formation of lamellipodia, loss of Rac-1 translocation to the membrane) resembles the previously described effects of
silencing of Cdk5 in endothelial cells. We conclude that especially LGR1406 and LGR1407 are highly attractive anti-
angiogenic compounds, whose effects seem to largely depend on their Cdk5 inhibiting properties.
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Introduction
Angiogenesis, the sprouting of new vessels from the existing
vasculature, mainly occurs during embryonic development and
growth. In the adult it is restricted to distinct physiological
processes, e.g. wound healing, by a balance of pro- and anti-
angiogenic factors [1]. Unregulated angiogenesis is one of the
hallmarks of cancer [2]. Tumor growth is highly dependent on
proper supply with oxygen and nutrients and removal of metabolic
waste. Therefore, angiogenesis is crucial for tumor survival and
proliferation, and tumor size remains limited unless the tumor
switches to an angiogenic phenotype [3]. The intent to stop tumor
growth and finally starve the tumor by disrupting angiogenic
signaling has led to the development of anti-angiogenic drugs for
anticancer therapy. Agents addressing vascular endothelial growth
factor (VEGF) induced angiogenesis have already been successfully
introduced into tumor therapy [4].
However, in clinical use it has become apparent that anti-
angiogenic tumor therapy is more challenging than expected:
Many tumors are refractory to VEGF-blockade or become
resistant during treatment. This evasive resistance [5] can be
caused by a shift to alternative angiogenic signaling pathways due
to a pre-existing multiplicity of redundant pro-angiogenic signals.
Therefore novel targets in angiogenesis need to be identified and
characterized as a basis for future therapeutic concepts.
Cdk5 has been discovered as a neuronal cdc2-like serine/
threonine kinase (nclk) in 1992 [6,7]. Despite its high sequence
homology with the mitotic Cdk1 (cdc2), Cdk5 is not involved in
cell cycle control and unique among the Cdks in its regulation and
function. On the cellular level, Cdk5 is well-described in neurons
as the key hub in the dynamic network of trafficking and transport,
integrating signals in cytoskeletal dynamics during neuronal
migration, in synaptic plasticity and synaptic vesicle endo- and
exocytosis, cell adhesion and axon guidance, neuromuscular
development and pain signaling [8,9]. Although Cdk5 expression
and activity is highest in the central nervous system [6], Cdk5 is
also expressed in various tissues, and an increasing body of
research uncovers extraneuronal functions of Cdk5, where it is
involved in the regulation of migration, cell death and survival,
glucose metabolism and inflammation [10,11].
(R)-roscovitine or CYC-202/seliciclib – in the following referred
to as roscovitine – belongs to the class of 2,6,9-trisubstituted
purines. It is one of the best-known Cdk inhibitors [12], and is
currently tested in several phase I and phase II clinical trials for
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tumor treatment [13]. Roscovitine inhibits mainly Cdk1, Cdk2,
Cdk5, Cdk7 and Cdk9 and exerts anti-mitotic and pro-apoptotic
effects in a wide range of tumor cells [14]. Cell-cycle independent
actions of roscovitine mainly derive from Cdk5 inhibition and
include anti-angiogenic [15] and anti-inflammatory [16] effects,
inhibition of cell migration and motility [17,18] and modulation of
glucose metabolism [19].
Anti-angiogenic actions of Cdk inhibitors have been observed in
vitro and in vivo [20,21,22]. Recently, we have demonstrated that
the anti-angiogenic effect of roscovitine most likely results from
impaired endothelial cell migration. The effect on migration was
traced down to Cdk5 inhibition which led to Rac1 inactivation
and lamellipodia disruption [15]. A promising novel strategy in
anti-angiogenic therapy may, therefore, be inhibition of Cdk5. To
date, improved Cdk inhibitors have mainly been developed in
order to block cancer cell proliferation but have not systematically
been optimized and evaluated for anti-angiogenic action. There-
fore, the aim of the present study was to evaluate the in vitro and in
vivo anti-angiogenic potency of newly prepared roscovitine-derived
Cdk inhibitors built on the pyrazolo[4,3-d]pyrimidine heterocyclic
core.
Results
Newly prepared pyrazolo[4,3-d]pyrimidine inhibitors of
Cdks
We have recently prepared 7-benzylamino-5(R)-[2-(hydroxy-
methyl)-propyl]amino-3-isopropyl-1(2)H-pyrazolo[4,3-d]pyrimidine
(compound LGR1404) as a bioisostere of the well-known Cdk
inhibitor roscovitine [23]. Our experiments proved that it is a more
potent Cdk inhibitor and also its anticancer activity in vitro exceeds
that of roscovitine. Therefore, and based on our knowledge of
structure-activity relationships for related purine Cdk inhibitors, we
have prepared a set of new and potent Cdk inhibitors with the
pyrazolo[4,3-d]pyrimidine scaffold (Figure 1A). Details on the
synthetic route are described in the Material and Methods section
and Figure 1B. The new compounds have been modified in
comparison to (R)-roscovitine in one or more of the following
aspects: 1) The purine scaffold has been changed to pyrazolo[4,3-
d]pyrimidine (LGR 1404, 1406, 1407, 1430, 1667, 1695). 2) In the
aminobenzyl group, an additional ortho amino function is present
(LGR 1430, 1695, 1730). 3) The residue at purine C2 or
pyrazolo[4,3-d]pyrimidine C5 differs from (R)-roscovitine either in
structure and/or stereochemistry.
Expression of Cdk5 in endothelial cells, cytotoxicity and
proliferation
Since Cdk5 has not been described to be present in HMEC-1
cells before, we compared the expression of Cdk5 in HMEC-1 to
that in HUVECs and in neuronal tissue (human cortex lysate as
positive control). HMEC-1 and HUVC expressed Cdk5 to a
similar amount, but to a lesser degree that cortex (about by half,
Figure 2A). To detect potential toxic effects on non-proliferating
endothelial cells in order to assess the systemic applicability of the
compounds, the impact of the novel Cdk inhibitors on viability
was tested in confluent monolayers. No reduced cell viability was
found for 10 mM of each of the inhibitors in comparison to
control. By contrast, 30 mM of LGR 1404, 1406, 1407, 1695 and
1730 displayed a weak but significant decrease of viability
(Figure 2B). Therefore, in the functional assays, the effects at
10 mM were used as selection criterion. As a first screening step
towards an anti-angiogenic potential, the novel inhibitors were
then tested in crystal violet proliferation assays with the endothelial
cell line HMEC-1. All seven compounds concentration-depen-
dently reduced endothelial cell proliferation (Figure 3), with an
IC50 between approximately 1 mM (LGR 1406) and 20 mM (LGR
1730). Microscopic analysis after 72 h of incubation with the
compounds at a concentration of 30 mM at the same cell density as
in the proliferation assay showed no increase of morphologically
altered, dead or detached cells, and no loss of membrane integrity
(Figure 4A with LGR 1406 as representative compound, other
compounds not shown).
Cell migration
Endothelial cell migration is the subsequent crucial step in
angiogenesis after the activation of the quiescent endothelial cells
to proliferate. All seven LGR compounds were tested in the
scratch assay for their effect on migration at the sub-toxic
concentration of 10 mM. Only LGR 1404, 1406 and 1407 were
able to significantly decrease endothelial cell migration at this
concentration. Treatment with 10 mM of the most potent
substances, LGR 1406 and 1407, reduced migration by 51%
and 31%, respectively (Figure 4B and C). In order to obtain more
detailed information on their mode of action on migration, the
active compounds were also tested in a chemotactic gradient of
FCS. Accumulative (as marker for overall cell migration) and
euclidean migration distance (as indicator of directionality), as well
as cell velocity were analyzed. All three compounds led to a
decrease in all determined migration indices (Figure 5).
Tube formation
The most powerful compounds from the migration experi-
ments, LGR 1404, 1406 and 1407 were chosen for tube formation
assays. 10 mM of LGR 1404, 1406 and 1407 all showed a
significant reduction of tube and branching point numbers as well
as of total tube length (Figure 6). LGR 1406 and 1407 again
showed the strongest effects. 10 mM of LGR 1406 decreased tube
length and number of branching points by 56%, and the tube
number by 42%. Treatment with 10 mM of LGR 1407 resulted in
an about 30% reduction of tube number and total tube length; and
to a 35% reduction in the number of branching points (Figure 6).
CAM Assay
The anti-angiogenic potency of the three most effective
compounds has been evaluated in vitro so far. In order to
substantiate these findings in vivo, chorioallantoic membrane
(CAM) assays were performed with LGR 1404, 1406 and 1407.
All three compounds completely abolished VEGF induced vessel
formation (Figure 7).
In vitro kinase profile
We found that LGR 1404, 1406 and 1407 were the most potent
compounds in all angiogenesis assays. Therefore, it was of interest
to see which kinases, especially which Cdks, are inhibited by those
compounds. The kinase profiling was performed by ProQinase
(Freiburg, Germany) for LGR 1406 and 1407. For LGR 1404
kinase profiling has recently been published previously [23]. LGR
1406 and 1407 were tested for their IC50 in a panel of 24 kinases,
including the Cdk1, Cdk2, Cdk4, Cdk5, Cdk6, Cdk7 and Cdk9.
The other kinases tested were PTK6, EGFR, FAK, FGFR1 and
FGFR2, NLK, PAK4, VEGFR1 and VEGFR2, MEK1, ROCK1,
RAF1, ALK, RSK3, AURKA, and AMPKa1.
The IC50 [M] of LGR 1406 and LGR 1407 for the Cdk/Cyclin
complexes are shown in Table 1. Both compounds inhibit mainly
Cdk2 and Cdk5, and to some extent Cdk9 and Cdk1. Concerning
the other tested kinases, FAK, PAK4, RSK3 and Aurora kinase A
are inhibited by LGR 1406 with an IC50 below 1610
25 M. LGR
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Figure 1. Chemical structures and synthesis of tested compounds in comparison to (R)-roscovitine. A: The LGR compounds have been
modified in comparison to (R)-roscovitine in one or more of the following aspects: 1) The purine scaffold has been changed to pyrazolo[4,3-
d]pyrimidine (LGR 1404, 1406, 1407, 1430, 1667, 1695), with LGR 1404 being a bioisoster of (R)-roscovitine. 2) In the aminobenzyl group, an additional
ortho amino function is present. (LGR 1430, 1695, 1730). 3) The residue at purine C2 or pyrazolo[4,3-d]pyrimidine C5 respectively, differs from (R)-
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1407 only inhibits Aurora kinase A (IC50#1610
25 M) in addition
to the Cdks displayed in Table 1.
Formation of lamellipodia and transcolation of Rac1 to
lamellipodia
In order to get an insight into the mechanism underlying the
anti-angiogenic action of the three most potent LGR, we analyzed
their effect on the formation of lamellipodia in migrating
endothelial cells. LGR 1404, 1406 and 1407 significantly
diminished the formation of lamellipodia by 54% (LGR 1404) to
67% (LGR 1406 and 1407) at 10 mM. This can be seen in the
respective images stained for f-actin (Figure 8A). To substantiate
this finding, we examined the localization of Rac1 to the cell front
of migrating cells. In immunofluorescence stainings we found a
decreased Rac1 localization to lamellipodia as displayed in
Figure 8B. Cortactin served as a marker protein for lamellipodia.
Discussion
We tested seven derivatives of the classical Cdk inhibitor
roscovitine as anti-angiogenic compounds in an approach where
the effect on endothelial migration was the crucial selection
criterion. This setting was chosen, since we have previously shown
that roscovitine and derivatives thereof had an anti-angiogenic
potential, which was based on the reduction of endothelial cell
motility via inhibition of Cdk5 [15,24]. The three compounds
which performed best in these and other functional assays (tube
formation and directed migration in a chemotactic gradient) in the
present work, LGR 1404, 1406 and 1407, also proved their anti-
angiogenic potency in vivo in CAM-assays, where they completely
inhibited VEGF-induced vessel formation. Thus, we have
identified three potent novel roscovitine derivatives that display
increased anti-angiogenic activity in comparison to their mother
substance roscovitine: while roscovitine itself only started to reduce
proliferation at a concentration of 30 mM [24], the three
roscovitine either in structure and/or stereochemistry. Defined configurations are shown in the chemical structures. LGR 1407 contains no
stereocenter. LGR 1406 and LGR 1430 are an equal mixture of 4 stereoisomers: the trans enantiomers (R, S) and (S, R); and the cis enantiomers (R, R)
and (S, S). B: The synthesis of new compounds and numbering of atoms for NMR spectra.
doi:10.1371/journal.pone.0054607.g001
Figure 2. Cdk5 is expressed in HUVECs and HMEC-1 cells, and the compounds are not cytotoxic to endothelial cells at
concentrations used in functional assays. A: Cdk5 protein expression in endothelial cells in comparison to human cortex. Cdk5 protein amount
was analyzed by Western blot in samples of human cortex (HC), confluent HUVECs (HU) and HMEC-1 (HM). b-actin served as a loading control and for
normalization of protein amount. Relative quantification (left panel) and one representative image (right panel) of three individual blots are shown.
Note the much lower protein loading in the HC sample in the right panel. (n = 3, mean 6 SEM, p.0.05, One Way ANOVA, Dunnett). B: Confluent
HUVECs were treated for 16 h with 10 or 30 mM of the indicated compounds or left untreated as control. After addition of CellTiter-BlueTM Reagent,
cells were incubated for 4 h and fluorescence was measured at 560 nm (n = 3, mean 6 SEM, * p,0.05, One Way ANOVA, Dunnett).
doi:10.1371/journal.pone.0054607.g002
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compounds LGR 1404, 1406 and 1407 had IC50 values of 7.72,
0.93 and 3.66 mM, respectively. Concerning migration, 10 mM
roscovitine yielded only 20% reduction [15], while the compounds
in the present work showed an inhibition between 30 and 50% at
an equimolar concentration. A similar difference was observed
during tube formation [15]. Roscovitine itself is termed a ‘‘pan
selective’’ inhibitor of Cdks, since it mainly addresses Cdk1, Cdk2,
Cdk5, Cdk7 and Cdk9. The selectivity data depend on the kinase
panel referred to [14,23,25,26]. LGR 1407 is equally potent in
inhibition of Cdk2 and Cdk5, and inhibits Cdk1 and Cdk9 to some
extent. LGR 1406 is by one order of magnitude more selective
towards Cdk5 and Cdk2 in comparison to Cdk1 and Cdk9. Both
compounds inhibited preferably Cdks in our kinase panel, with
LGR 1407 showing a higher Cdk selectivity. Comparing the two
most powerful compounds LGR 1406 and 1407, the lower IC50
for Cdk5 and the higher selectivity for Cdk5 (and Cdk2) of LGR
1406 mirror the effect in the angiogenesis assays. LGR 1407 is
more selective towards Cdk5 in comparison to LGR 1404, which
mainly inhibits Cdk2 (IC50 for Cdk2 0.22 mM, for Cdk5 0.94 mM
according to Jorda et al. [23]). This is probably the reason why
LGR 1404 is the least potent anti-angiogenic compound of the
three with regard to the in vitro data.
Since we have previously shown by silencing experiments that
Cdk5 influences endothelial migration via a reduction of activated
Rac1 [15], a small GTPase of central importance for lamellipodia
formation and cell motility, we also determined the effect of LGR
1404, 1406 and 1407 on lamellipodia formation and Rac1
localization, as an indicator of Cdk5 inhibition. Due to their
respective effects, we suggest that their mode of action is indeed
the potent inhibition of Cdk5 and not Cdk2. The lower selectivity
Figure 3. All tested compounds concentration-dependently inhibit proliferation of endothelial cells. HMEC-1 cells were seeded to a
density of 1,500 cells/well. After 24 h of incubation, a zero point control was stained with crystal violet. The remaining cells were left untreated as
positive control or treated with 0.3-1-3-10–30 mM of the indicated compounds. After 72 h additional incubation, relative proliferation was determined
by crystal violet staining and quantified as absorption at 550 nm.
doi:10.1371/journal.pone.0054607.g003
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of LGR 1404 for Cdk5 becomes also apparent in the lamellipodia
quantification and the Rac1/lamellipodia immunofluorescence
images: the disruption of lamellipodia and the effect on Rac1 is not
that prominent as with LGR 1406 and LGR 1407.
In order to adapt the structure of the Cdk inhibitors for optimal
anti-angiogenic potential, the relation of structural changes and
anti-angiogenic effect is of interest. For the LGR compounds as
roscovitine derivatives, the structure was modified in three points:
1) Changing the purine scaffold to a pyrazolo[4,3-d]pyrimidine:
In general, the change of the scaffold led to a higher anti-
angiogenic potency of the substances. All substances chosen
for further evaluation after the migration assay share the
pyrazolo[4,3-d]pyrimidine scaffold. Direct comparison of the
potency of roscovitine and its pyrazolo[4,3-d]pyrimidine
bioisoster, LGR 1404, substantiates this observation. The
only compound tested with a purine scaffold, LGR 1730,
showed the weakest effect on proliferation and no significant
impact on migration (data not shown).
2) Ortho-amino function in the aminobenzyl group at C6
(purine) or C7 (pyrazolo[4,3-d]pyrimidine): The presence of
an amino group rather seems to decrease the anti-angiogenic
potential of the compounds. The compounds LGR 1430 and
LGR 1492 differ from LGR 1406 and LGR 1404,
respectively, only in the presence of the amino function,
and show both weaker effects. This is especially obvious in the
comparison of LGR 1406 and LGR 1430 as LGR 1406 was
the most potent compound in the assays, whereas LGR 1430
showed no detectable effect on migration at 30 mM (data not
shown).
Figure 4. LGRs do not reduce cell numbers by inducing cell death and LGR 1404, 1406 and 1407 significantly reduce endothelial
cell migration at 10 mM. A: HMEC-1 cells were seeded in the same density as for the proliferation assay and treated with the respective compound
at 30 mM for 72 h to test whether reduced cell numbers in the proliferation assay are due to inhibition of proliferation or to excessive cell death. No
increase of detached, obviously dead or propidium iodide positive cells was detected. B and C: Confluent layers of HUVECs were scratched and the
cells were allowed to migrate for 16 h in the presence or absence of 10 mM of the compounds. B: The columns indicate the area re-covered by
migrating cells (n = 3, mean 6 SEM, * p,0.05, One Way ANOVA, Dunnett). C: Scratches at endpoint, representative images taken out of three
experiments.
doi:10.1371/journal.pone.0054607.g004
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3) Variation of the side chain at C2 (purine) or C5 (pyr-
azolo[4,3-d]pyrimidine): Evaluating the impact of different
side chains on the anti-angiogenic effect is difficult as the
compounds differ from roscovitine in more than one
structural property and no direct comparison is possible. By
trend, a bulky side chain like the substituted sec-butyl- (e.g.
LGR 1404) or cyclohexyl- (e.g. LGR 1406) groups seem to
increase anti-angiogenic potency.
In conclusion, we have demonstrated that LGR 1404, 1406 and
1407 are able to potently inhibit angiogenesis in vitro via a Cdk5-
dependent mechanism and show a higher potency and selectivity for
Cdk5 in comparison to the established Cdk5 inhibitor roscovitine.
Their impact on Cdk5 parallels the efficacy in the angiogenesis
assays which supports the strategy of Cdk5 inhibition as a powerful
new approach in anti-angiogenic therapy. For the further
development of anti-angiogenic roscovitine derivatives, compari-
son of the structures of the tested LGR inhibitors shows a positive
correlation to anti-angiogenic potency for the pyrazolo[4,3-
d]pyrimidine scaffold and a negative correlation for an additional
amino function in the benzyl group.
Materials and Methods
Studied compounds and general chemical procedures
7-Benzylamino-5(R)-[(1-hydroxymethyl)propylamino]-3-isopro-
pyl-1(2)H-pyrazolo[4,3-d]pyrimidine (compound LGR1404), 7-
benzylamino-3-isopropyl-5-methylsulfonyl-1(2)H-pyrazolo[4,3-d]py-
rimidine and 7-(2-aminobenzylamino)-3-isopropyl-5-methylsulfonyl-
1(2)H-pyrazolo-[4,3-d]-pyrimidine (precursors of the synthesis
described here) have been prepared according to the published
procedures [23]. All other studied compounds have been synthe-
sized according to the scheme shown in Figure 1B.
Melting points were determined on a Kofler block and are
uncorrected. NMR spectra have been measured on a Bruker
300 MHz spectrometer (75 MHz, respectively for 13C) in DMSO-
d6 or CDCl3 at 303 K. The residual solvent signal has been used as
an internal standard (dH 2.500, dC 39.60 for DMSO- d6, or dH
7.265, dC 77.00 for CDCl3).
1H NMR, 13C NMR, COSY, HSQC,
HMBC have been measured using standard manufacturers’
software (Varian Inc., Palo Alto, USA). Chemical shifts are given
in d-scale [ppm] and coupling constants in Hz. Some 13C signals
of the heterocycle were not visible due to bad relaxation. ESI or
APCI mass spectra were determined using a Waters Micromass
ZMD mass spectrometer (direct inlet, coin voltage 20 V). Merck
silica gel Kieselgel 60 (230–400 mesh) was used for column
chromatography. Compound purity was determined by elemental
analyses (0.4%) or HPLC-MS analysis and was confirmed to be
.95% for all compounds.
7-Benzylamino-5(R)-[(2-hydroxypropyl)amino]-3-
isopropyl-1(2)H-pyrazolo[4,3-d]pyrimidine (compound
LGR1667)
Methylsulfone 1 (0.25 g, 0.72 mmol) and R-(-)-3-amino-2-
propanole 0.6 mL (7 mmol) were heated in sealed ampoule for
5 h to 120uC. Excess of the amine was evaporated at a
temperature below 70uC and the residue was partitioned between
CHCl3/H2O. The combined organic phases were dried with
magnesium sulfate and evaporated. Product was purified by
column flash chromatography on silica gel stepwise with 4, 5, 6, 7,
8% MeOH in CHCl3. The product was obtained in a non-
crystallisable amorphous and colourless glass 72 mg, yield 29%,
[a]D =224.2u (c = 1 g/l, CHCl3, 20uC) MS ESI
+: [M+H]+
=341,4 (100%), [2M+H]+ =681 (4%), MS ESI2: [M2H]2
=339,3 (100%). 1H-NMR (300 MHz, CDCl3): 1.182 d (3H,
Figure 5. LGR 1404, 1406 and 1407 decrease chemotaxis of endothelial cells. Chemotaxis of HUVECs in the presence or absence of 10 mM
of the indicated compounds was determined in m-slides Chemotaxis. A: Quantitative evaluation of accumulated and euclidean distance, velocity and
y-forward migration index (n = 3, mean 6 SEM, * p,0.05, One Way ANOVA, Dunnett). B: Representative cell tracking plots of untreated and treated
cells.
doi:10.1371/journal.pone.0054607.g005
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J=6.2 Hz, 23), 1.202 d (6H, J=6.6 Hz, 19), 3.114 sept (1H,
J=7.0 Hz, 18), 3.260–3.410 m (2H, 21), 3.974 m (1H, 22),
4.666 s (2H, 11), 5.400 bs (1H, NH or OH), 7.200–7.276 m (5H,
ArH). 13C-NMR (75 MHz, CDCl3): 20.2 (23), 20.9 (11), 25.4 (18),
43.7 (11), 49.9 (21), 69.2 (22), 126.5, 126.8, 127.2, 128.0, 137.5,
158.4. Anal. (C18H24N6O) C, H, N.
5-[(2-E/Z-aminocyclohexyl)amino]-7-benzylamino-3-
isopropyl-1(2)H-pyrazolo[4,3-d]pyrimidine (compound
LGR1406)
Methylsulfone 1 (0.3 g, 0.87 mmol) and (E/Z)-1,2-diaminocy-
clohexane 2.8 mL were heated in sealed ampoule for 8 h to
Figure 6. LGR 1404, 1406 and 1407 inhibit tube formation at 10 mM. HUVECs were seeded onto a matrix of growth-factor reduced
MatrigelTM in the presence or absence of the respective concentration of the compounds. After 16 h of incubation, images were taken and tube
characteristics were quantified. A: Number of tubes (n = 3, mean 6 SEM, * p,0.05, One Way ANOVA, Dunnett). B: Number of branching points (n = 3,
mean6 SEM, * p,0.05, One Way ANOVA, Dunnett). C: Tube total length (n = 3, mean6 SEM, * p,0.05, One Way ANOVA, Dunnett). D: Representative
images of the tube formation assay and the software based tube recognition (structures identified as tubes are blue) in a control (Co, left panel) and
after treatment with LGR 1406 (10 mM, right panel).
doi:10.1371/journal.pone.0054607.g006
Figure 7. LGR 1404, 1406 and 1407 completely inhibit VEGF-induced vessel formation in the chorioallantoic membrane (CAM)
assay. Fertilized white leghorn eggs were incubated for 72 h at 37uC in humidified atmosphere. After transferring the growing embryo into Petri
dishes, a second incubation period of 72 h followed. At day 6, cellulose discs with 2.5 ng VEGF/250 nmol compound were placed on the membrane.
2.5 ng VEGF/DMSO was used as control. Pictures were taken after 24 h of stimulation. Representative images out of at least three experiments are
shown.
doi:10.1371/journal.pone.0054607.g007
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145uC. Excess of the amine was evaporated at a temperature
below 70uC and the residue was partitioned between CHCl3/
H2O. The combined organic phases were dried with sodium
sulfate and evaporated. Product was purified by column flash
chromatography on silica gel stepwise with 8, 10, 12, 14% MeOH
in CHCl3 with a trace of concentrated NH4OH. The product was
obtained in a non-crystallisable amorphous colorless glass 49 mg,
yield 15%, MS ESI+: [M+H]+ =380.4 (100%), MS ESI2:
[M2H]2 =378.4 (100%). 1H-NMR (300 MHz, DMSO-d6):
1.01–1.31 m (3H, 24a, 24b, 25a), 1.32 d (6H, J=7.0 Hz, 19),
Table 1. Cdk inhibition profile of LGR 1406 and 1407.
Cdk1/CycB Cdk2/CycA Cdk2/CycE Cdk4/CycD1 Cdk5/p25 Cdk6/CycD1 Cdk7/CycH/MAT1 Cdk9/CycT
LGR
1406
3.261026 9.961027 5.961027 1.561025 4.461027 .1024 .1024 1026
LGR
1407
5.861026 1.561026 9.961027 6.661025 1.661026 9.161025 .1024 1.961026
The numbers given are IC50 values (molar). Both compounds show an increased selectivity for Cdk2 and Cdk5.
doi:10.1371/journal.pone.0054607.t001
Figure 8. LGR 1404, 1406 and 1407 decrease lamellipodia formation in migrating cells, and inhibit recruitment of Rac1 to
lamellipodia. A: Confluent layers of HUVECs were scratched and the cells were allowed to migrate for 8 h in the presence or absence of the
respective concentration of the compounds, until clear lamellipodia formation was visible in the control. The actin cytoskeleton was then stained with
rhodamin-phalloidine and fluorescence images (10x magnification) of the scratches were taken. Left panel: For quantitative evaluation of lamellipodia
formation, cells with prominent lamellipodia and ruffles were counted in relation to the number of cells at the scratch front (n = 3, mean 6 SEM, *
p,0.05, One Way ANOVA, Dunnett). Right panel: Representative images of the scratch front (f-actin, 40x magnification). B: Cells treated like in A were
fixed and stained for f-actin (red), cortactin (green) and Rac1 (white). Representative images out of three experiments are shown.
doi:10.1371/journal.pone.0054607.g008
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1.44–1.68 m (3H, 23a, 23b, 26a), 1.84 bd (1H, 25b), 2.01 bd (1H,
26b), 2.54 m (1H, 22), 3.16 sept (1H, J=7.0 Hz, 18), 3.43 m (1H,
21), 4.68 s (2H, 11), 5.82 d (1H, J=7.7 Hz, 20), 7.25 t (1H, 15),
7.34 t (2H, 14+16), 7.39 d (2H, 13+17), 7.75 bs (1H, 10), 11.98 bs
(1H, 1). 13C-NMR (75 MHz, DMSO-d6): 21.6 (19); 21.7 (19); 24.8
(24); 24.9 (25); 25.8 (18); 31.9 (26); 34.3 (23); 43.0 (11); 54.0 (22);
57.1 (21); 126.8 (15); 127.5 (13+17); 128.3 (14+16); 136.0; 139.6
(12); 145.7; 150.6 (7); 157.4; 158.1; 168.6. Anal. (C21H29N7) C, H,
N.
5-[(4-E-aminocyclohexyl)amino]-7-benzylamino-3-
isopropyl-1(2)H-pyrazolo[4,3-d]pyrimidine (compound
LGR1407)
Methylsulfone 1 (0.3 g, 0.87 mmol) and (Z)-1,4-diaminocyclo-
hexane 4.5 g were heated in sealed ampoule for 8 h to 145uC.
Excess of the amine was evaporated at a temperature below
70uC and the residue was partitioned between CHCl3/H2O.
The combined organic phases were dried with sodium sulfate
and evaporated. Product was purified by column flash chroma-
tography on silica gel stepwise with 8, 10, 12, 14% MeOH in
CHCl3 with a trace of concentrated NH4OH. Product was
obtained in a form of non-crystallisable amorphous colourless
glass 57 mg, yield 17%, MS ESI+: [M+H]+ =380.3 (100%), MS
ESI2: [M2H]2 =378.4 (100%). 1H-NMR (300 MHz, DMSO-
d6): 1.04–1.27 m (4H, 22, 23), 1.32 d (6H, J=7.0 Hz, 19), 1.76
bd (2H, J=10.0 Hz, 25), 1.90 bd (2H, J=10.0 Hz, 26), 2.54 m
(1H, 24), 3.15 sept (1H, J=7.0 Hz, 18), 3.6 m (1H, 21), 4.66 d
(2H, J=5.3 Hz, 11), 5.71 d (1H, J=7.9 Hz, 20), 7.24 t (1H, 15),
7.33 t (2H, 14+16), 7.38 d (2H, 13+17), 7.73 t (1H, J=5.3 Hz,
10), 12.13 bs (1H, 1). 13C-NMR (75 MHz, DMSO-d6): 21.6 (19);
25.8 (18); 31.3 (22+21); 34.8 (23+25); 42.9 (11); 49.4 (21); 49.9
(24); 121.0; 126.8 (15); 127.4 (13+17); 128.2 (14+16); 139.6 (12);
140.0 (3); 144.7 (9); 150.6 (7); 157.3 (5). Anal.(C21H29N7) C, H,
N.
7-(2-Aminobenzyl)amino-5(R)-[(2-hydroxypropyl)amino]-
3-isopropyl-1(2)H-pyrazolo[4,3-d]pyrimidine (compound
LGR1730)
Methylsulfone 2 (0.4 g, 1.1 mmol) and R(-)-3-amino-2-propa-
nole 1 mL were heated in a sealed ampoule for 5 h to 120uC.
Excess of the amine was evaporated at a temperature below 70uC
and the residue was partitioned between CHCl3/H2O. The
combined organic phases were dried with magnesium sulfate and
evaporated. Product was purified by column flash chromatogra-
phy on silica gel stepwise with 4, 5, 7, 10% MeOH in CHCl3,
crystallized from CHCl3-Et2O, mp 186–189uC, 71 mg, yield 18%,
[a]D =214.8u (c = 1 g/l, CHCl3, 20uC), MS ESI
+: [M+H]+
=356.3 MS ESI2: [M2H]2 =354.3 (100). 1H-NMR (300 MHz,
CDCl3): 1.186–1.311 m (9H, 19+23), 3.185 sept (1H, J=7.0 Hz,
18), 3.370–3.530 m (2H, 21), 3.920–4.061 m (1H, 22), 4.657 s
(2H, 11), 6.150 bs (1H, NH), 6.622–6.699 m (2H, ArH), 7.058–
7.141 m (2H, ArH), 8.199 s (1H, OH). 13C-NMR (300 MHz,
CDCl3): 19.9 (23), 20.3 (19), 25.2 (18), 44.9 (11), 49.8 (21), 66.4
(22), 115.4, 117.7, 121.2, 126.5, 128.7, 130.2, 133.9, 144.7, 153.2,
161.3, 175.0. Anal. (C18H25N7O) C, H, N.
7-(2-Aminobenzyl)amino-5(S)-[(2-hydroxypropyl)amino]-
3-isopropyl-1(2)H–pyrazolo[4,3-d]pyrimidine (compound
LGR1695)
The compound has been prepared using the same synthetic
process as for R antipode. Analytic data are the same as for R
antipode, with the exception of [a]D = +15.2u (c = 1 g/l, CHCl3).
7-(2-Aminobenzyl)amino-5-[(2-E/Z-
aminocyclohexyl)amino]-3-isopropyl-1(2)H-pyrazolo-[4,3-
d]pyrimidine (compound LGR1430)
Methylsulfone 2 (0.4 g, 1.1 mmol) and (E/Z)-1,2-diaminocy-
clohexane 5 mL were heated in a sealed ampoule for 8 h to
145uC. Excess of the amine was evaporated at a temperature
below 70uC and the residue was partitioned between CHCl3/
H2O. The combined organic phases were dried with sodium
sulfate and evaporated. Product was purified by column flash
chromatography on silica gel stepwise with 8, 10, 12, 14% MeOH
in CHCl3 with a trace of concentrated NH4OH. Product was
obtained in a form of non-crystallisable amorphous colourless glass
55 mg, yield 13%, MS ESI+: [M+H]+ =395.3 MS ESI2:
[M2H]2 =393.4 (100). 1H-NMR (300 MHz, DMSO-d6):
1.03–1.26 m (3H, 24a, 24b, 25a), 1.32 d (6H, J=7.0 Hz, 19),
1.51–1.68 m (3H, 23a, 23b, 26a), 1.84 d (1H, J=10.0 Hz, 25b),
2.06 d (1H, J=12.4 Hz, 26b), 2.54 m (1H, 22), 3.15 sept (1H,
J=7.0 Hz, 18), 3.29 bs (2H, 27), 3.38 m (1H, 21), 4.53 d (2H, 11,
J=5.3 Hz), 5.14 bs (2H, 28), 5.86 d (1H, J=7.7 Hz, 20), 6.51 t
(1H, J=7.3 Hz, 16), 6.64 d (1H, J=7.9 Hz, 14), 6.97 t (1H,
J=7.9 Hz, 15), 7.12 d (1H, J=7.3 Hz, 17), 7.50 bs (1H, 10),
11.98 bs (1H, 1). 13C-NMR (75 MHz, DMSO-d6): 21.5 (19); 21.6
(19); 24.9 (24); 25.0 (25); 25.8 (18); 31.9 (26); 34.7 (23); 39.7 (11);
54.1 (22); 57.4 (21); 114.6 (14); 115.7 (16); 121.9 (12); 123.1; 127.3;
127.9 (15); 129.5 (17); 139.8; 145.7 (13); 150.4; 158.1; 160.7. Anal
(C21H30N8) C, H, N.
Cell culture
Endothelial cells (HMEC-1 Human microvascular endothelial
cells and HUVECs Human umbilical vein endothelial cells) were
cultured in growth medium (ECGM, Promocell, Heidelberg,
Germany) containing 10% fetal calf serum as previously described
[27]. The cell line HMEC-1 (CDC/EU.HMEC-1) was kindly
provided by the Centers for Disease Control and Prevention
(Atlanta, GA, USA) [28]. HUVECs were freshly isolated from
umbilical cords placed in PBS containing Ca2+/Mg2+, penicillin
(100 U/ml), and streptomycin (100 mg/ml). The umbilical vein
was cannulated, flushed with PBS+Ca2+/Mg2+, filled with 0.1 g/l
collagenase A, and incubated for 45 min at 37uC. The eluted cell
suspension was centrifuged (1,000 rpm, 5 min). Afterwards, cells
were resuspended and plated in a 25 cm2 flask (passage #0). After
reaching confluency, cells were trypsinized and plated in a 75 cm2
flask. Unless otherwise indicated, experiments were performed
using cells at passage #3. All patients with no special risks before
giving birth were routinely asked for their consent for using
anonymous tissue materials for non-profit research. Since no risk
or additional encumbrance was induced by collecting the
umbilical cords, the local ethics committee had not to be informed
in this case.
Western blot
Samples were lysed in RIPA buffer, frozen at 280uC,
centrifuged at 14,000 rpm for 10 min at 4uC, and heated in
Laemmli buffer at 95uC for 5 min. Equal amounts of protein were
loaded on discontinuous polyacrylamide gels, consisting of a
separation and a stacking gel, and separated using the Mini-
PROTEAN 3 electrophoresis module (Bio-Rad, Munich, Ger-
many). The molecular weight of proteins was determined by
comparison with a prestained protein ladder (PageRulerTM,
Fermentas, St. Leon-Rot, Germany). After protein separation,
proteins were transferred to a nitrocellulose membrane (Hybond-
ECLTM, Amersham Bioscience, Freiburg, Germany) by tank
electroblotting in the Mini Trans-BlotH system (Bio-Rad, Munich,
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Germany). Cdk5 was detected by incubation with a polyclonal
rabbit antibody (C-8) from Santa Cruz. Equal loading was
controlled by detecting b actin mouse polyclonal C4 from
Millipore).
Cell viability assay
HUVECs were seeded in 96-well plates. After reaching
confluency, the cells were treated for 16 h with the indicated
compounds or left untreated as control. After addition of
CellTiter-BlueTM Reagent (Promega Corporation, Madison, WI,
USA), cells were incubated for additional 4 h and fluorescence was
measured at 560 nm in a plate-reading photometer (SpectraFluor
Plus; Tecan, Crailsheim, Germany).
Proliferation assay
HMEC-1 were seeded into 96-well-plates (1,500 cells/well).
After 24 h, the cells were stimulated with the indicated
compounds. At the same time point, cells in a reference plate
were stained with crystal violet, serving as initial cell number. After
72 hours of stimulation, cells were fixed and stained with crystal-
violet solution for 10 minutes, washed with water, and air dried.
Crystal violet was eluted with dissolving buffer and absorbance
was measured at 550 nm (Tecan Sunrise Absorbance reader,
TECAN, Crailsheim, Germany). In a parallel series of experi-
ments, cells seeded at the same cell density as in the proliferation
assays were treated with 30 mM of the respective compound for
72 h. Afterwards, 10 mg/ml propidium iodide was added for
30 min to counterstain cells for membrane integrity. Phase
contrast and fluorescence images were obtained with an inverted
Nikon microscope (Ti, Nikon, Du¨sseldorf, Germany) equipped
with a 10x objective.
Scratch assay (migration assay)
HUVECs were seeded into a 24-well plate. After reaching
confluency, cells were scratched using a 100 ml pipette tip. The
wounded monolayers were washed twice with PBS containing
Ca2+/Mg2+; then growth medium containing the indicated
concentration of the compounds was added. After 16 h of
migration, cells were washed and subsequently fixed with 4%
paraformaldehyde. In previous experiments we have shown that
under these conditions cell proliferation does not contribute
substantially to scratch closure [15]. Images were taken using the
TILLvisON system (TILL Photonics GmbH, Gra¨felfing, Ger-
many) and a CCD-camera connected to an Axiovert 200
microscope (Zeiss, Oberkochen, Germany). Quantitative image
analysis of the cell covered area was done by Wimasis GmbH,
Munich. A completely closed scratch was set as 100% migration,
the area of the original open scratch was set as 0% migration.
Chemotaxis assay
The effect of the LGR compounds on endothelial cell
chemotaxis was determined using Collagen IV coated m-slides
Chemotaxis (ibidi, Martinsried, Germany). HUVECs (56106 cells
per ml) were seeded into the observation channel of the slides
according to the manual of the manufacturer, and the cells were
allowed to attach for 4 hours. Then, the chambers of the
chemotaxis slide were completely filled with serum-free medium
M 199; and growth medium containing 30% FCS was added to
one chamber in order to generate an FCS-gradient from 0% to
10%. 10 mM of the indicated compounds were added both to the
M199 and to the 30% FCS. Chemotaxis was observed over
20 hours by live-cell imaging with a Zeiss LSM 510 META
confocal microscope equipped with an incubator stage (EMBLem,
Heidelberg, Germany). A time series was collected taking 1 picture
every 10 minutes. For cell tracking and data analysis, the manual
tracking plug-in (Fabrice Cordelieres) and the Chemotaxis and
Migration Tool (Version 1.01, ibidi, Martinsried, Germany) for
ImageJ were used. Euclidean distance (direct distance from the
starting point to the end point) was used as an indicator of
directionality of movement, accumulative distance (sum of all
migrated distances from track to track) and velocity (mean velocity
of every cell calculated as ratio between track to track distance and
time) were used as a measure for total motility.
Tube formation assay
Pre-cooled BD MatrigelTM Matrix Growth Factor Reduced
(GFR) (BD Biosciences, Heidelberg, Germany) was filled into the
lower compartment of m-slide Angiogenesis wells (ibidi GmbH,
Martinsried, Germany) on ice. For polymerization of the
MatrigelTM Matrix, the slides were incubated at 37uC for
30 min. 12,000 HUVECs/well were seeded onto the MatrigelTM
and stimulated for 16 h. The extent of tube formation was
determined by light microscopy using the TILLvisON system.
Quantitative image analysis of tube length, number of branching
points and tube number was performed with a software tool from
Wimasis GmbH, Munich.
Chorioallantoic membrane (CAM) assay
Fertilized white leghorn eggs were incubated for 72 h at 37uC in
humidified atmosphere. After transferring the growing embryo
into a Petri dish, a second incubation period of 72 h followed. At
day 6, two cellulose discs, one with 2.5 ng VEGF (VEGF 165,
human recombinant from PeproTech GmbH, Hamburg, Ger-
many)/250 nmol compound and the other with 2.5 ng VEGF/
DMSO as control were placed on one CAM. After 24 h of
stimulation, the vascular structure in the stimulated areas of the
CAM was visualized using a stereomicroscope and a CCD camera
(Olympus, Munich, Germany) and pictures were taken. The
cellulose disks were produced as follows: after preparing a cellulose
solution (2.5% hydroxyethyl cellulose, 2% polyvinylpyrrolidone
(PVP 17), 2% polyethylene glycol (PEG 400) in water), the mixture
was autoclaved, resulting in a homogenized, clear solution. For
each disk, 200 ml of the warm solution were filled into the
preformed circles of the lid of a 96 well plate and allowed to
polymerize under a laminar air flow for 48 h. Finally, the cellulose
disks were removed using tweezers and stored in a sterile Petri dish
until use.
Quantification of lamellipodia and immunocytochemistry
Confluent layers of HUVECs were scratched and stimulated in
8-well m-slides as described above. The cells were allowed to
migrate for 8 h in the presence or absence of the respective
concentration of the compounds, until clear lamellipodia forma-
tion was visible in the control. The actin cytoskeleton was then
stained with rhodamine-phalloidin (Life Technologies, Darmstadt,
Germany) and fluorescence images of the scratches were taken in
10x magnification with the Zeiss LSM 510 META. For
quantitative evaluation of lamellipodia formation, cells with
prominent lamellipodia and ruffles were counted with ImageJ
(Cell Counter plug-in by Kurt De Vos) in relation to the total
number of cells at the scratch front. The ratio was calculated as
number of lamellipodia-positive cells per 100 cells at scratch front.
In the same setting immunofluorescence staining was performed.
Fixed cells were permeabilized for 2 min with 0.1% Triton X-100
in PBS. Cells were washed and unspecific binding was blocked
with 0.2% BSA in PBS for 15 min. Thereafter, cells were
incubated with primary antibody (cortactin: rabbit polyclonal,
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1:100, Cell Signaling, and Rac1: mouse monoclonal, 1:100,
Upstate) in 0.2% BSA/PBS over night at 4uC. After three washing
steps with PBS, the specimen were incubated with the corre-
sponding AlexaFluorH -labeled secondary antibodies for 30 min at
room temperature. Finally, the slides were again washed three
times with PBS (5 min), embedded in FluorSaveTM Reagent
mounting medium and covered with 8 mm 68 mm glass cover
slips.
Statistical Analysis
The number of independently performed experiments is stated
in the respective figure legend. Bar graph data are mean values 6
SEM. Statistical analysis was performed with the GraphPad Prism
software version 3.03 (GraphPad Software, San Diego, CA, USA).
For statistical comparison of groups one-way ANOVA followed by
Dunnett post hoc test was used. Values of p,0.05 were considered
statistically significant. Graph Pad Prism was used for curve fitting
(nonlinear, sigmoidal dose response curves with a variable slope
based on a Hill Emax model), and for calculation of the IC50
values for each compound.
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